This article aimed to report two cases of Burkitt lymphoma/leukemia with concurrent t(8; 14) and t( 14; 18). Morphology, immunophenotype, cytogenetics and molecular biology (MICM) methods were applied to diagnosis. The results showed that the two cases were both acute lymphocytic leukemia L3 type according to FAB criteria. Conventional cytogenetic technique or interphase fluorescence in situ hybridization (FISH) demonstrated that t(8; 14) and t(14;18) were detected concurrently in both patients. CD20, CD10, FMC7, CD38 and CD19 were expressed in both patients by immunophenotyping. According to MICM, they were both diagnosed as Burkitt lymphoma/leukemia. The first patient died in one month after chemotherapy, and the second patient survived 19 months after rituximab-combined high-dose chemotherapy and subsequently allogeneic hematopoietic stem cell transplantation ( HSCT). In conclusion, t ( 8; 14) and t (14; 18 ) may present simultaneously in Burkitt lymphoma/leukemia and indicate poor prognosis. Rituximab-combined chemotherapy and subsequently HSCT could improve the outcomes of such cases.%本文报告2例同时伴有t(8；14)和t(14；18) Burkitt淋巴瘤白血病的实验诊断及临床特征.采用形态学、免疫分型、细胞遗传学及分子生物学( MICM)方法对2例患者的实验室特征进行分析.结果显示:2例患者按FAB分型均为急性淋巴细胞白血病L3型,常规细胞遗传学或荧光原位杂交检测证实2例患者同时具有t(8；14)和t(14；18)染色体易位,免疫表型均表达CD20、CD10、FMC7、CD38、CD19.综合MICM,2例患者均诊断为Burkitt淋巴瘤白血病.1例患者经化疗后1个月内死亡,1例患者经美罗华和大剂量化疗后接受造血干细胞移植已健康存活19个月.结论:t(8；14)和t(14；18)可同时存在于Burkitt淋巴瘤白血病,t(8；14)和t(14；18)并存提示预后不良.含美罗华的联合化疗方案加造血干细胞移植可有效改善患者的不良预后.
展开▼
